Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke
J. Clin. Invest. Woei-Cherng Shyu, et al. 118:133 doi:10.1172/JCI32723 [Go to this article.]

Figure 3
SN administration i.v. in cerebral ischemic rats improves neurological dysfunction and reduces infarct size. (A) From 14 to 28 days after treatment, ischemic rats receiving SN i.v. showed significantly reduced body asymmetry after MCA ligation compared with controls. (B–D) Rats receiving SN showed significantly increased locomotor activities 14–28 days after treatment. (E) Final results of grip strength measurements showed a higher grip strength ratio in the SN-treated rats than in control rats. (F and G) Representative images of ischemic brain MRI; the white areas (white arrows) are the infarcted zones in the right cerebral cortices of the SN-treated and control rats on days 1, 7, and 28 after cerebral infarction. (H) Quantitation of the infarct volume showed significant reduction in rats treated with SN on the seventh day after cerebral ischemia compared with controls. The area of largest infarction in the ischemic brain and the number of infarcted sections per rat were also reduced by SN treatment. (I) Representative ¹⁸FDG-PET (coronal view) of the right cortices (black arrows) of SN-treated and control rats. (J) Semiquantitative measurement showed that relative glucose metabolic activity in the right cortex, shown as the ratio of the ispilateral hemisphere to the contralateral hemisphere, was much greater in the SN-treated group than in the control group. Data are mean ± SEM. *P < 0.05, **P < 0.01 vs. control.